Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8938824 | 0.90 | OPRM1 (0.48) | OPRM1DRD4MEN1KMT2ASCN1A | |
| SCHEMBL8935595 | 0.90 | HRH1 (0.46) | OPRM1DRD4MEN1KMT2ACHRM1 | |
| SCHEMBL8935605 | 0.88 | MAOA (0.48) | DRD4ACHESCN1ASCN8ADRD2 | |
| SCHEMBL8935163 | 0.86 | ROCK1 (0.52) | OPRM1BCHEACHEKMT2AHRH1 | |
| SCHEMBL8937951 | 0.86 | ROCK1 (0.52) | OPRM1DRD4BCHEACHEMEN1 | |
| SCHEMBL8935590 | 0.85 | MAOB (0.49) | OPRM1DRD4BCHEACHEDRD2 | |
| SCHEMBL8938841 | 0.84 | OPRM1 (0.43) | OPRM1DRD4BCHEACHESCN1A | |
| SCHEMBL8935571 | 0.84 | MAOA (0.52) | OPRM1DRD4BCHEACHESCN1A | |
| SCHEMBL8935610 | 0.83 | HRH1 (0.43) | DRD4SCN1ASCN8ADRD2HRH1 | |
| SCHEMBL8936649 | 0.82 | HRH1 (0.41) | OPRM1DRD4BCHEACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | OPRM1 3345/4885DRD4 4443/4885BCHE 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.